Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Checkpoint Inhibitor Induced Immune-related Adverse Events
NCT07694414Phase 1Recruiting
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in immune-related adverse events (irAEs). Primary endpoint: Incidence and severity of rituximab-related adverse events at 6 months. Started Oct 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT07694414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694414.